太極集團(600129.SH):子公司生產的藥品中有散列通,適用於緩解感冒或流感引起的發熱
格隆匯8月13日丨太極集團(600129.SH)在投資者互動平臺表示,根據國家衛生健康委、國家中醫藥局綜合司《關於印發基孔肯雅熱診療方案(2025年版)的通知》,基孔肯雅熱(Chikungunyafever,CHIK)是由基孔肯雅病毒(Chikungunyavirus,CHIKV)感染引起,經伊蚊叮咬傳播的急性傳染病。臨牀以發熱、關節痛、皮疹爲主要特徵。目前尚無特異性治療方法,以對症支持治療爲主。其中對症治療的方法包括:退熱、以物理降溫爲主。高熱不退者推薦使用對乙酰氨基酚,應避免使用阿司匹林等非甾體類抗炎藥(NSAIDs)。鎮痛、急性期關節疼痛不能忍受者,可使用對乙酰氨基酚。 公司下屬子公司西南藥業股份有限公司生產的藥品中有散列通(通用名複方對乙酰氨基酚片Ⅱ),適用於緩解感冒或流感引起的發熱,以及頭痛、牙痛、關節痛等多種疼痛症狀,是解熱鎮痛類藥物。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.